Jakob Kohler

Dr. Jakob Kohler

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
LBLeonhard Buck
Leonhard Buck
JKJakob Kohler
Jakob Kohler
JRJulian Risch
Julian Risch
RIReha-Baris Incesu
Reha-Baris Incesu
KHKonrad Hügelmann
Konrad Hügelmann
SRSeverin Rodler
Severin Rodler
Background: Multimodal artificial intelligence (MMAI) is transforming urological oncology by enabling the seamless integration of diverse data sources, including imaging, clinical records and robotic telemetry to facilitate patient-specific decision-making. Methods: This narrative review summarizes the current developments, applications, opportunities and risks of multimodal AI systems throughout the entire perioperative process in uro-oncologic surgery. Results: MMAI demonstrates quantifiable benefits across the entire perioperative pathway. Preoperatively, it improves diagnostics and surgical planning via multimodal data fusion. Intraoperatively, AI-assisted systems provide real-time context-based decision support, risk prediction and skill assessment within the operating theater. Postoperatively, MMAI facilitates automated documentation, early complication detection and personalized follow-up. Generative AI further revolutionizes surgical training through adaptive feedback and simulations. However, critical limitations must be addressed, including data bias, the barrier of closed robotic platforms, insufficient model validation, data security issues, hallucinations and ethical concerns regarding liability and transparency. Conclusions: MMAI significantly enhances the precision, efficiency and patient-centeredness of uro-oncological care. To ensure safe and widespread implementation, resolving the technical and regulatory barriers to real-time integration into robotic platforms is paramount. This must be coupled with standardized quality controls, transparent decision-making processes and responsible integration that fully preserves physician autonomy.

1 June 2026 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Open access
JKJakob Kohler
Jakob Kohler
LBLeonhard Buck
Leonhard Buck
PSPatricia Schließer
Patricia Schließer
OWOscar Weische
Oscar Weische
JRJulian Risch
Julian Risch
SRSeverin Rodler
Severin Rodler
To evaluate whether exposure to glucagon-like peptide-1 receptor agonists (GLP-1) or sodium-glucose cotransporter 2 inhibitors (SGLT2) is associated with overall survival (OS) in adults with treated bladder cancer. We conducted a retrospective cohort study using de-identified electronic health records from the TriNetX Global Collaborative Network (2013-2024). Adults with bladder cancer receiving surgery, chemotherapy, and/or radiotherapy were classified as GLP-1 receptor agonist- or SGLT2 inhibitor-exposed vs. nonexposed (mutual class exclusion). Treatment had to occur within ±3 months of the bladder cancer criterion for GLP-1 receptor agonist and within ±3 months for SGLT2 inhibitors. Exposed and nonexposed cohorts were propensity-score matched 1:1 on demographics, comorbidities, and concomitant medications. OS was assessed from day 1 through day 3650 after the index event. After matching, 5,294 GLP-1 receptor agonist users were compared with 5,294 nonusers, and 5,356 SGLT2 inhibitor users with 5,356 nonusers. Mortality was lower with GLP-1 receptor agonist exposure (934 vs. 1,855 deaths; hazard ratio for nonuse vs. use 1.915, 95% CI, 1.770-2.073; P < 0.001) and with SGLT2 inhibitor exposure (1,325 vs. 2,099 deaths; hazard ratio 1.232, 95% CI, 1.148-1.322; P < 0.001). In 6- and 12-month landmark sensitivity analyses the associations attenuated but remained statistically significant. In these large, propensity-matched, multicenter real-world cohorts of treated bladder cancer, GLP-1 receptor agonist and SGLT2 inhibitor exposure were each associated with improved OS. Limitations include residual confounding and limited granularity for tumor stage and treatment intent; prospective and mechanistic studies are needed to assess causality and clinical utility.

12 November 2025 in Journal of Robotic Surgery
Verified
Journal Article
Open access
PDF file
JKJakob Kohler
Jakob Kohler
LBLeonhard Buck
Leonhard Buck
KHKonrad Hügelmann
Konrad Hügelmann
RIReha-Baris Incesu
Reha-Baris Incesu
HKHans Christoph von Knobloch
Hans Christoph von Knobloch
PNPhilipp Nuhn
Philipp Nuhn
Background: Obesity is an increasing comorbidity in patients undergoing radical cystectomy. While robot-assisted radical cystectomy (RARC) has been widely adopted, evidence for its safety in overweight patients remains limited. Methods: We retrospectively analyzed 337 consecutive patients who underwent RARC or open radical cystectomy (ORC) at a European tertiary center (2013–2024). Outcomes were stratified by body mass index (BMI) and assessed by regression and non-inferiority analyses. Results: In the presented cohort (135 normal-weight and 202 overweight patients) urinary-diversion patterns (continent vs. incontinent) did not differ by BMI or approach. RARC required longer operative times than ORC, but BMI itself had no independent effect. The length of stay (LOS) was shorter after RARC with BMI increasing LOS only in the ORC group. Adjusted models identified ORC as an independent predictor of prolonged stay. Non-inferiority of RARC in overweight patients was demonstrated for both length of stay ( p = 0.044) and Clavien–Dindo-graded perioperative morbidity. Conclusion: RARC delivers robust perioperative safety in overweight patients, maintaining non-inferiority for morbidity and LOS. These findings support the use of RARC as a standard approach to radical cystectomy, including in obese populations.

17 February 2026 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
JKJakob Kohler
Jakob Kohler
LBLeonhard Buck
Leonhard Buck
KHKonrad Hügelmann
Konrad Hügelmann
RIReha-Baris Incesu
Reha-Baris Incesu
HKHans Christoph von Knobloch
Hans Christoph von Knobloch
SRSeverin Rodler
Severin Rodler
Purpose: Chronological age influences selection for radical cystectomy in bladder cancer, yet biological vulnerability may be more informative. We assessed perioperative outcomes and overall survival after robot-assisted radical cystectomy (RARC) and developed a pragmatic age–Eastern Cooperative Oncology Group (ECOG) risk score. Methods: Consecutive RARC patients (August 2013–December 2024) were analyzed retrospectively and grouped by age (< 75, 75–79, 80–84, ≥ 85 years). Ninety-day complications were graded by Clavien–Dindo classification. Overall survival (OS) was estimated by Kaplan–Meier methods. An age threshold for overall mortality was derived by receiver operating characteristic analysis (Youden index). The risk score assigned one point each for age above the cut-off and ECOG performance status ≥ 2. Cox regression adjusted for Charlson Comorbidity Index and pathological T stage. Results: Among 171 patients, length of stay and overall complications did not differ statistically across age strata, although comparisons are limited by selection and the small ≥ 85 subgroup. OS differed by age cohort ( p = 0.00013) with an optimal age threshold of 76.5 years ( p < 0.0001). ECOG ≥ 2 predicted worse survival ( p < 0.0001), and the score separated 1, 2 and 3 score groups ( p < 0.0001). On multivariable analysis, age > 76.5 years remained independently associated with worse overall survival (hazard ratio 2.72, 95% confidence interval 1.58–4.68; p < 0.001). Conclusion: RARC is feasible across advanced age strata in selected patients, but survival varies substantially. A simple age threshold plus ECOG performance status may aid counseling and perioperative planning and warrants external validation.

1 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SRSeverin Rodler
Severin Rodler
SLStephan T. Ledderose
Stephan T. Ledderose
RWRaphaela Waidelich
Raphaela Waidelich
JKJakob Kohler
Jakob Kohler
ASAndrea Sendelhofert
Andrea Sendelhofert
LELennert Eismann
Lennert Eismann
Immune checkpoint inhibition is a cornerstone of bladder cancer therapy, but its efficacy in non-urothelial subtypes of bladder cancer is limited, and the prognosis remains poor. Therefore, we investigated the potential of the immune checkpoint molecules TIM-3, TIGIT, and LAG-3 in squamous-cell carcinoma (SCC) and adenocarcinoma (ADENO) of the urinary bladder. Tumor-infiltrating lymphocytes (TILs) showed a high expression of TIM-3 and TIGIT in both SCC and ADENO, while LAG-3-positive TILs were absent in ADENO and present in 46% of SCC. Quantitative analysis revealed age-independent expression of TIM-3 in SCC (r = −0.001, p = 0.997) and ADENO (r = 0.135, p = 0.549), with increasing age correlating with higher expression of TIGIT (r = 0.157, p = 0.242) and LAG-3 (0.106, p = 0.436) in the SCC cohort and of TIGIT (r = 0.276, p = 0.214) in the ADENO cohort. Male patients showed increased TIGIT scores in ADENO (p < 0.01). Of note, a high infiltration of TIM-3-TILs (p = 0.048) correlated with worse progression-free survival in SCC. These results highlight the differential expression of co-inhibitory receptors in non-urothelial bladder cancer subtypes and provide preclinical evidence for new therapeutic targets. Biomarker testing prior to clinical trials is essential for identifying the most suitable patients for targeted immunotherapy.

2 October 2026 in BJUI Compass
Verified
Journal Article
Open access
JRJulian Risch
Julian Risch
KHKonrad Hügelmann
Konrad Hügelmann
LBLeonhard Buck
Leonhard Buck
HKHans‐Christoph von Knobloch
Hans‐Christoph von Knobloch
JKJakob Kohler
Jakob Kohler
SRSeverin Rodler
Severin Rodler
Objectives: This study aims to assess patient acceptance of intraoperative video recording with Operating Room (OR) black box technology, characterise consent conditions and use‐case preferences, and identify predictors of patient confidence in artificial intelligence (AI)‐assisted surgery in urological patients. Patients and Methods: This prospective cross‐sectional survey was conducted at the urology department of a university hospital from March 2024 to March 2025. Consecutive adults scheduled for elective procedures were enrolled (322 enrolled; 316 completed the binary consent item). A standardised questionnaire assessed consent to operative video storage and attitudes across four Likert‐scaled domains (29 items: consent conditions, use cases, data access and AI confidence). The primary outcome was confidence in AI‐assisted surgery for the full procedure. Analysis included Wilson 95% confidence intervals, between‐group comparisons and multivariable linear regression. Results: Of 316 patients (82.9% male, mean age 65.4 years), 304 (96.2%, 95% CI 93.5–97.8%) consented to operative video storage, with universal acceptance among oncological patients (181/181, 100%). Nonconsenters ( n = 12) were younger, without oncological diagnosis and reported lower AI confidence. All 29 attitudinal items received majority endorsement. Patient confidence in AI‐assisted surgery was expressed by 55.2% for the full procedure, 63.5% for simple steps and 53.9% for complex steps ( p < 0.001). Older patients expressed greater confidence ( r ₛ = −0.21, p < 0.001). Age and three attitudinal composites independently predicted AI confidence (adjusted R 2 = 0.308), whereas demographic and clinical characteristics accounted for only 5.8% of variation. Conclusion: Urological patients broadly accept intraoperative recording and AI‐assisted surgery when transparent governance is ensured. Attitudinal factors outweigh demographic and clinical characteristics, supporting patient‐centred consent frameworks for OR black box implementation in urological practice.